Leading Performance Beauty Company Launches New Collection of Injectable Hyaluronic Acid (HA) Gels

Performance beauty company, Evolus, has announced the European commercial launch of Estyme® — a new collection of injectable hyaluronic acid (HA) gels designed to support practitioners in delivering refined, natural-looking aesthetic outcomes.

Launched across Europe on 16 May 2026, Estyme® marks Evolus’ entry into the international dermal filler market and represents a significant milestone in the company’s strategy to become a leading multi-product aesthetics business. The collection has achieved CE Mark certification under the European Medical Device Regulation (MDR), one of the world’s most rigorous regulatory frameworks, confirming its compliance with strict standards for safety, quality, and performance.

The Estyme® portfolio comprises four HA injectable gels, including Estyme® Smooth, Estyme® Form, Estyme® Lips, and Estyme® Sculpt. The collection is designed to address a wide range of aesthetic applications, giving practitioners greater flexibility when tailoring treatments to individual patient needs.

Estyme® Smooth and Estyme® Form are already available in the United States under the Evolysse® brand, while Estyme® Lips and the flagship Estyme® Sculpt make their debut in Europe. Developed specifically for restoring mid-face volume, Estyme® Sculpt targets one of the most sought-after treatment areas in aesthetic medicine, helping practitioners address age-related volume loss while maintaining natural facial harmony.

At the heart of the Estyme® technology is Cold-X® technology, developed by Symatese. This innovative approach is designed to preserve the natural structure of the hyaluronic acid molecule, supporting product performance and enabling long-lasting, natural-looking results.

David Moatazedi, President and Chief Executive Officer of Evolus, said the launch represents an important step forward for the company’s international growth.

“With the commercial launch of Estyme®, we are entering a new phase of growth as a multi-product aesthetics company in Europe,” he said. “We are especially excited to introduce Estyme® Sculpt to practitioners, a product we believe has the potential to become a leader in mid-face volumising treatments.”

The launch also strengthens Evolus’ position as one of the companies offering both a neurotoxin and dermal filler portfolio internationally.

UK cosmetic surgeon and founder of Define Clinic, Dr Benji Dhillon, welcomed the arrival of Estyme® in Europe, highlighting the importance of technology that supports subtle and personalised results.

“The Cold-X® technology is designed to preserve the integrity of the hyaluronic acid, which is important when aiming for refined, natural-looking outcomes,” he explained. “Having a versatile range of gels that can be used across different treatment areas gives practitioners greater flexibility and confidence in delivering personalised results for patients.”

Clinical studies conducted in the United States have demonstrated strong performance across the Evolysse® collection, including studies showing non-inferiority and statistical superiority compared with a leading comparator in head-to-head trials.

With global demand for injectable aesthetics continuing to evolve, the launch of Estyme® marks an important expansion of treatment options for European practitioners. By combining advanced HA gel technology, a comprehensive product portfolio, and Evolus’ established commercial infrastructure, the company aims to support the next generation of aesthetic treatments focused on precision, personalisation and natural beauty.

For practitioners, the arrival of Estyme® offers a new set of tools designed to enhance patient choice and help achieve balanced, confidence-boosting results across multiple facial indications.